Clinical trial · Interventional
Efficacy of Myofascial Pain Syndrome Treatment in Patients With Cancer in Palliative Care
Treatment of Myofascial Pain Syndrome With Lidocaine Injection in Patients With Cancer in Palliative Care: a Randomized Clinical Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Palliative Care is active holistic care offered to people who are in intense suffering related to their health, resulting from a serious life-threatening illness, with a focus on improving the quality of life. Among the symptoms that cause suffering, physical pain has a prominent role in terms of prevalence and impact on well-being, especially in the subgroup of patients with terminal cancer. Myofascial Pain Syndrome may be one of the components of pain in cancer patients in palliative care. However, the literature is scarce in defining the prevalence of this condition in this population, and there is no evidence of the benefit of needling treatment with 1% lidocaine in these patients until now. The objectives of this study are to determinate the prevalence of myofascial pain syndrome and to evaluate the effectiveness of myofascial pain treatment with 1% lidocaine injection in reducing pain in palliative cancer patients, comparing it with a control group in usual care.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Myofascial Pain Syndromes | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 1% lidocaine injection in trigger points | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1% lidocaine injection
- description
- The intervention group will be submitted to the trigger point injection procedure with 1% lidocaine (the sum of all needled trigger points will have a maximum of 10 ml), in a single intervention
- interventionNames
- Combination Product: 1% lidocaine injection in trigger points
- type
- NO_INTERVENTION
- label
- Control Group
- description
- The control group will receive usual care, defined as the treatment for pain prescribed by their assistant doctors.
Primary outcomes (1)
- measure
- Change in pain intensity
- timeFrame
- 72 hours and 7 days
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Participants that 1. accomplish the Travel and Simons' diagnostic criteria for myofascial pain syndrome, 2. have pain intensity on visual analog scale of 5 or more, 3. have performance status on the Karnofsky Performance Status scale of 30 or more. Exclusion Criteria: * Use of high dose anticoagulants (RNI above the therapeutic range); * Patients with hemorrhagic diathesis; * Patients with moderate to severe dementia syndrome; * Patients with diagnosis of acute confusional state during the follow-up; * Occurrence of clinical complication or intervention that could compromise the reevaluation of pain in the following days (for example, undergoing a surgical procedure or nerve block) or death.
References
Publications (1)
- DERIVEDSantos-Vilar LAD, Freitas-Passos IF, Rossi BM, Blauth FG, Pontes VCB, Moriguti JC, Riberto M, Lima NKDC. Lidocaine Needling in Myofascial Pain Syndrome for Palliative Oncologic Care: A Randomized Clinical Study. J Palliat Med. 2024 Jul;27(7):888-894. doi: 10.1089/jpm.2023.0641. Epub 2024 Mar 14. PMID 38484328